This grant by the Department of Health and Human Services supports the World Health Organization in overseeing smallpox research activities, including advising on research with variola virus and biosafety inspections. The grant aims to ensure global public health security by monitoring essential research progress and aiding in potential medical countermeasure development for smallpox threats. The focus is on supporting non-research activities related to variola virus research, as mandated by international agreements and health regulations. The grant is solely awarded to the World Health Organization and contributes to maintaining preparedness against any re-emergence or deliberate use of smallpox, emphasizing the importance of biosafety and health regulations.
Opportunity ID: 285330
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-007 |
| Funding Opportunity Title: | Smallpox Research Oversight Activities: WHO Advisory Committee on Variola Virus Research |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.019 — Technical Assistance and Provision for Foreign Hospitals and Health Organizations |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 22, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 22, 2016 Applications must be submitted electronically via http://www.grants.gov by August 21, 2016 at 11:59 pm EST. |
| Current Closing Date for Applications: | Aug 22, 2016 Applications must be submitted electronically via http://www.grants.gov by August 21, 2016 at 11:59 pm EST. |
| Archive Date: | Sep 21, 2016 |
| Estimated Total Program Funding: | $300,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility Category(s): Non-domestic (non-US) Entities (Foreign Institution) |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | Smallpox is an acute contagious disease caused by variola virus, a member of the Orthopoxvirus genus. It was one of the world’s most feared diseases until it was eradicated by a collaborative global vaccination program led by the World Health Organization. The last known natural case was in Somalia in 1977. Upon eradication, all existing stockpiles of the virus were moved, by international agreement, to two ÂWHO International Collaborating Centers. The Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, USA, and the State Research Center of Virology and Biotechnology, Novosibirsk, Russia. Under this agreement, any and all work with variola virus by either group must be directly approved through an oversight committee established by the WHO. The WHO Advisory Committee on Variola Virus Research (ACVVR) was established in 1999 to determine what essential research, if any, must be carried out with live variola virus. The ACVVR monitored the research progress in order to reach global consensus on the timing for the destruction of existing variola virus stocks. In 2007, the World Health Assembly (WHA) requested the ACVVR undertake a thorough review of the approved research program with a report presented in 2010. The results were presented at the 64th WHA meeting in May of 2011. The ACVVR continues to serve a critically important function for global public health, and to oversee research. The U.S. Government supports the development of medical products, including vaccines and drugs, for use within the U.S. upon verification of a smallpox case. The U.S. government, through the Office of the Assistant Secretary for Preparedness and Response (ASPR), has successfully developed vaccine products, and is actively engaged in the development of several drug candidates for smallpox therapies, which require access to the variola virus to satisfy regulatory requirements for product approvals. The U.S. maintains a need to work directly with the virus for its strategic needs in developing medical countermeasures, such as safer vaccines, new antiviral agents, and better diagnostic systems as a defense against potential bioterrorism threats, thus strengthening our national security. A natural re-emergence of smallpox is not deemed possible, but if it were to occur as a result of a terrorist or deliberate event, it would be a potentially devastating threat to public health worldwide and would constitute a public health emergency of international concern (PHEIC) under the International Health Regulations (IHR) (2005). A case of smallpox detected by a member state requires notification to WHO as soon as possible, and any confirmed smallpox case would generate an immediate global public health response. Since May 1999, when the 52nd World Health Assembly (WHA) resolved to postpone the destruction of the variola virus to allow for this essential research (WHA 52.10), WHO has been charged with convening a group of experts to advise on the need for continuing such research, to review proposals for research involving viable variola virus, to review the progress of such research, and to report to the WHA each year. The need to support the activities described in this FOA has not changed. The variola virus research and stocks destruction are expected to be substantive agenda items at the 70th World Health Assembly in 2017. ASPR will provide a single source cooperative agreement to support the WHO Advisory Committee on Variola Virus Research to advise WHO on all activities in respect to variola virus research and the biosafety inspection of the variola virus repositories. The only eligible awardee is the World Health Organization (WHO). This FOA will only support non-research activities supported by HHS. |
| Link to Additional Information: | Smallpox Research Oversight Activities: WHO Advisory Committee on Variola Virus Research |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:www.grants.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | Grants.gov Contact Center Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email: www.grants.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.019 | EP-IDS-16-007-057723 | WHO Smallpox Research Oversight Activities | PKG00224861 | Jun 22, 2016 | Aug 22, 2016 | View |
Package 1
Mandatory forms
285330 SF424_2_1-2.1.pdf
285330 SF424A-1.0.pdf
285330 SF424B-1.1.pdf
285330 GG_LobbyingForm-1.1.pdf
285330 Project_Abstract-1.1.pdf
285330 Project-1.1.pdf
Optional forms
285330 Other-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
